## Diagnosis: Pancytopenia Secondary to Cirrhosis with Portal Hypertension ### Clinical Context: Cirrhosis-Associated Pancytopenia **Key Point:** Pancytopenia in a cirrhotic patient with splenomegaly and normal bone marrow cellularity is pathognomonic for **splenic sequestration** (hypersplenism), not bone marrow failure. **High-Yield:** The triad that defines hypersplenism: 1. Splenomegaly (here: 16 cm) 2. Cytopenias (pancytopenia in this case) 3. Normal or hyperplastic bone marrow (confirmed by exam) ### Pathophysiology of Hypersplenism in Cirrhosis ```mermaid flowchart TD A[Cirrhosis]:::outcome --> B[Portal hypertension]:::outcome B --> C[Increased splenic blood flow]:::outcome C --> D[Splenic congestion]:::outcome D --> E[Splenic pooling of RBC, WBC, platelets]:::outcome E --> F[Reduced circulating cells]:::outcome F --> G[Pancytopenia]:::outcome B --> H[Splenomegaly develops]:::outcome H --> I[Mechanical sequestration increases]:::outcome I --> E ``` **Mechanism Breakdown:** | Pathophysiologic Step | Mechanism | Result | |---|---|---| | **Portal hypertension** | Fibrosis/cirrhosis → increased intrahepatic resistance | Splenic venous pressure ↑ | | **Splenic congestion** | Increased blood pooling in splenic sinusoids | Spleen enlarges (up to 20–30 cm) | | **Sequestration** | RBC, WBC, platelets preferentially pool in congested spleen | Circulating counts ↓ | | **Bone marrow response** | Marrow compensates with increased production | Marrow remains normocellular or hyperplastic | | **Net result** | Pancytopenia with normal/hyperplastic marrow | Diagnosis: hypersplenism | **Clinical Pearl:** The bone marrow is **normal or hyperplastic**, not aplastic. This distinguishes hypersplenism from primary bone marrow failure (aplastic anemia, MDS, leukemia). ### Why This Patient Has Hypersplenism, Not Other Causes **Evidence from the case:** - **Splenomegaly (16 cm):** Massive; consistent with portal hypertension - **Normal marrow cellularity with adequate megakaryocytes:** Rules out aplastic anemia, MDS, leukemia - **Normocytic, normochromic RBC:** No evidence of hemolysis (would be macrocytic with reticulocytosis) - **Cirrhosis with INR 1.8, low albumin:** Hepatic synthetic function impaired, but this is NOT the primary cause of cytopenias - **Chronic HCV:** Background, but virus does not directly infiltrate marrow or cause immune destruction in this context **Mnemonic — Hypersplenism vs. Bone Marrow Failure: "MARROW"** - **M**arrow cellularity: Normal/hyperplastic in hypersplenism; hypoplastic in aplasia - **A**natomy: Splenomegaly in hypersplenism; normal spleen in aplasia - **R**eticulocyte count: Normal/low in hypersplenism; low in aplasia - **R**isk of bleeding: Thrombocytopenia in both, but hypersplenism has normal marrow response - **O**ther cytopenias: All cell lines affected equally in hypersplenism - **W**hite cell response: Normal marrow production in hypersplenism; impaired in aplasia ### Why Other Options Are Incorrect **Option 0 (Hepatic synthetic failure → impaired growth factors):** - While cirrhosis does impair hepatic synthesis (albumin, clotting factors, thrombopoietin), the bone marrow is **not hypoplastic**—it is normal/hyperplastic. - If synthetic failure were the primary mechanism, marrow would be hypocellular. - Hepatic failure contributes to coagulopathy (INR 1.8) but not directly to pancytopenia in this context. **Option 2 (Autoimmune destruction):** - No evidence of autoimmune hemolytic anemia (normal reticulocyte count, normocytic RBC, no elevated LDH/indirect bilirubin mentioned). - Chronic HCV can cause cryoglobulinemia and vasculitis, but not primary immune cytopenias in cirrhosis. - Marrow is normal, not showing immune infiltration or destruction. **Option 3 (Direct HCV infiltration of marrow):** - Hepatitis C does not cause primary bone marrow infiltration. - HCV-associated cytopenias are indirect (via cirrhosis, cryoglobulinemia, or rarely immune mechanisms), not from direct viral marrow invasion. - Marrow cellularity is normal, ruling out infiltration. ### Clinical Management Implications **Key Point:** Recognizing hypersplenism is crucial because: 1. **Transfusion may be needed** for severe cytopenias, but marrow will compensate 2. **Splenectomy** is rarely indicated (risk of portal vein thrombosis in cirrhosis) 3. **Treatment focuses on cirrhosis:** Antivirals for HCV, management of portal hypertension (beta-blockers, variceal prophylaxis) 4. **Prognosis:** Cytopenias improve with successful HCV eradication and cirrhosis stabilization [cite:Harrison 21e Ch 96; Robbins 10e Ch 13]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.